OPNT Annual SG&A
$16.73 M
+$299.70 K+1.82%
31 December 2021
Summary:
As of February 5, 2025, OPNT annual selling, general & administrative expenses is $16.73 million, with the most recent change of +$299.70 thousand (+1.82%) on December 31, 2021. During the last 3 years, it has risen by +$5.25 million (+45.75%).OPNT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT Quarterly SG&A
$5.67 M
-$1.16 M-16.94%
30 September 2022
Summary:
As of February 5, 2025, OPNT quarterly selling, general & administrative expenses is $5.67 million, with the most recent change of -$1.16 million (-16.94%) on September 30, 2022. Over the past year, it has increased by +$1.23 million (+27.74%).OPNT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT TTM SG&A
-$316.67 M
-$33.09 M-11.67%
30 September 2022
Summary:
As of February 5, 2025, OPNT TTM selling, general & administrative expenses is -$316.67 million, with the most recent change of -$33.09 million (-11.67%) on September 30, 2022. Over the past year, it has dropped by -$333.07 million (-2031.88%).OPNT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.8% | +27.7% | -2031.9% |
| 3 y3 years | +45.8% | +69.2% | -2572.3% |
| 5 y5 years | +164.5% | +41.0% | -2572.3% |
OPNT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | at high | -47.5% | -1398.1% |
Opiant Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | $5.67 M(-16.9%) | $24.39 M(+5.3%) |
| June 2022 | - | $6.83 M(-2.6%) | $23.16 M(+15.3%) |
| Mar 2022 | - | $7.01 M(+43.3%) | $20.09 M(+20.1%) |
| Dec 2021 | $16.73 M(+1.8%) | $4.89 M(+10.2%) | $16.73 M(+2.1%) |
| Sept 2021 | - | $4.44 M(+18.1%) | $16.39 M(+5.1%) |
| June 2021 | - | $3.76 M(+3.1%) | $15.60 M(-5.0%) |
| Mar 2021 | - | $3.64 M(-20.0%) | $16.42 M(-0.0%) |
| Dec 2020 | $16.43 M(+28.3%) | $4.55 M(+25.0%) | $16.43 M(+8.4%) |
| Sept 2020 | - | $3.64 M(-20.5%) | $15.15 M(+2.0%) |
| June 2020 | - | $4.58 M(+25.6%) | $14.86 M(+13.7%) |
| Mar 2020 | - | $3.65 M(+11.3%) | $13.08 M(+2.1%) |
| Dec 2019 | $12.81 M(+11.6%) | $3.28 M(-2.2%) | $12.81 M(+3.9%) |
| Sept 2019 | - | $3.35 M(+19.9%) | $12.32 M(+4.1%) |
| June 2019 | - | $2.80 M(-17.3%) | $11.83 M(-0.5%) |
| Mar 2019 | - | $3.38 M(+21.0%) | $11.89 M(+3.6%) |
| Dec 2018 | $11.48 M(+81.4%) | $2.79 M(-2.3%) | $11.48 M(+32.2%) |
| Sept 2018 | - | $2.86 M(+0.1%) | $8.68 M(-11.8%) |
| June 2018 | - | $2.86 M(-3.6%) | $9.84 M(+6.1%) |
| Mar 2018 | - | $2.96 M(-26.2%) | $9.28 M(-15.2%) |
| Dec 2017 | $6.33 M(-22.7%) | - | - |
| Oct 2017 | - | $4.02 M(+75.5%) | $10.94 M(+33.8%) |
| July 2017 | $8.18 M(-44.8%) | $2.29 M(+10.1%) | $8.18 M(+12.7%) |
| Apr 2017 | - | $2.08 M(-18.5%) | $7.26 M(+15.0%) |
| Jan 2017 | - | $2.55 M(+102.9%) | $6.31 M(-0.8%) |
| Oct 2016 | - | $1.26 M(-8.1%) | $6.36 M(-60.0%) |
| July 2016 | $14.83 M(+145.7%) | $1.37 M(+20.8%) | $15.90 M(+0.3%) |
| Apr 2016 | - | $1.13 M(-56.5%) | $15.85 M(-4.4%) |
| Jan 2016 | - | $2.60 M(-75.9%) | $16.58 M(+2.9%) |
| Oct 2015 | - | $10.79 M(+714.8%) | $16.12 M(+167.1%) |
| July 2015 | $6.03 M(-44.3%) | $1.32 M(-28.9%) | $6.03 M(-29.1%) |
| Apr 2015 | - | $1.86 M(-12.9%) | $8.51 M(+19.2%) |
| Jan 2015 | - | $2.14 M(+202.1%) | $7.14 M(-29.0%) |
| Oct 2014 | - | $708.00 K(-81.4%) | $10.06 M(-7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2014 | $10.84 M(+27.2%) | $3.80 M(+669.1%) | $10.84 M(+32.3%) |
| Apr 2014 | - | $494.50 K(-90.2%) | $8.19 M(-0.6%) |
| Jan 2014 | - | $5.06 M(+241.4%) | $8.24 M(-11.8%) |
| Oct 2013 | - | $1.48 M(+28.4%) | $9.35 M(+9.3%) |
| July 2013 | $8.52 M(-27.9%) | $1.15 M(+112.0%) | $8.55 M(-5.0%) |
| Apr 2013 | - | $544.60 K(-91.2%) | $9.00 M(-7.8%) |
| Jan 2013 | - | $6.17 M(+801.7%) | $9.76 M(+20.3%) |
| Oct 2012 | - | $683.90 K(-57.4%) | $8.11 M(-31.5%) |
| July 2012 | $11.83 M(+25.4%) | $1.60 M(+23.3%) | $11.83 M(-8.9%) |
| Apr 2012 | - | $1.30 M(-71.2%) | $12.99 M(-24.0%) |
| Jan 2012 | - | $4.52 M(+2.5%) | $17.08 M(+26.0%) |
| Oct 2011 | - | $4.41 M(+59.7%) | $13.56 M(+43.7%) |
| July 2011 | $9.44 M(+367.9%) | $2.76 M(-48.9%) | $9.44 M(+31.8%) |
| Apr 2011 | - | $5.40 M(+442.8%) | $7.16 M(+261.9%) |
| Jan 2011 | - | $994.70 K(+253.0%) | $1.98 M(-11.0%) |
| Oct 2010 | - | $281.80 K(-41.8%) | $2.22 M(+10.2%) |
| July 2010 | $2.02 M(>+9900.0%) | $484.40 K(+122.8%) | $2.02 M(+31.5%) |
| Apr 2010 | - | $217.40 K(-82.5%) | $1.53 M(+16.1%) |
| Jan 2010 | - | $1.24 M(+1525.7%) | $1.32 M(+1445.0%) |
| Oct 2009 | - | $76.20 K(+4382.4%) | $85.50 K(+481.6%) |
| July 2009 | $14.70 K(-17.9%) | $1700.00(-60.5%) | $14.70 K(-41.2%) |
| Apr 2009 | - | $4300.00(+30.3%) | $25.00 K(+10.6%) |
| Jan 2009 | - | $3300.00(-38.9%) | $22.60 K(0.0%) |
| Oct 2008 | - | $5400.00(-55.0%) | $22.60 K(+26.3%) |
| July 2008 | $17.90 K(-31.2%) | $12.00 K(+531.6%) | $17.90 K(-0.6%) |
| Apr 2008 | - | $1900.00(-42.4%) | $18.00 K(-15.1%) |
| Jan 2008 | - | $3300.00(+371.4%) | $21.20 K(+14.6%) |
| Oct 2007 | - | $700.00(-94.2%) | $18.50 K(-0.5%) |
| July 2007 | $26.00 K | $12.10 K(+137.3%) | $18.60 K(+186.2%) |
| Apr 2007 | - | $5100.00(+750.0%) | $6500.00(+242.1%) |
| Jan 2007 | - | $600.00(-25.0%) | $1900.00(+46.2%) |
| Oct 2006 | - | $800.00(+60.0%) | $1300.00(+160.0%) |
| Apr 2006 | - | $500.00(>+9900.0%) | $500.00(>+9900.0%) |
| Jan 2006 | - | $0.00 | $0.00 |
FAQ
- What is Opiant Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals annual SG&A year-on-year change?
- What is Opiant Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals quarterly SG&A year-on-year change?
- What is Opiant Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals TTM SG&A year-on-year change?
What is Opiant Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of OPNT is $16.73 M
What is the all time high annual SG&A for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high annual selling, general & administrative expenses is $16.73 M
What is Opiant Pharmaceuticals annual SG&A year-on-year change?
Over the past year, OPNT annual selling, general & administrative expenses has changed by +$299.70 K (+1.82%)
What is Opiant Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of OPNT is $5.67 M
What is the all time high quarterly SG&A for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $10.79 M
What is Opiant Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, OPNT quarterly selling, general & administrative expenses has changed by +$1.23 M (+27.74%)
What is Opiant Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of OPNT is -$316.67 M
What is the all time high TTM SG&A for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high TTM selling, general & administrative expenses is $24.39 M
What is Opiant Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, OPNT TTM selling, general & administrative expenses has changed by -$333.07 M (-2031.88%)